Effects of probiotic administration on immune responses of children and adolescents with type 1 diabetes to a quadrivalent inactivated influenza vaccine. Issue 1 (2nd January 2020)

• Record Type: Journal Article
• Authors: Bianchini, Sonia; Orabona, Ciriana; Camilloni, Barbara; Berioli, Maria Giulia; Argentiero, Alberto; Matino, Davide; Alunno, Anna; Albini, Elisa; Vacca, Carmine; Pallotta, Maria Teresa; Mancini, Giulia; Tascini, Giorgia; Toni, Giada; Mondanelli, Giada; Silvestri, Ettore; Grohmann, Ursula; Esposito, Susanna
• Is Part Of: Human vaccines & immunotherapeutics. Volume 16:Issue 1(2020)
• Page Start: 86
• Page End: 94
• Publication Date: 2020-01-02
• Subjects: influenza -- influenza vaccine -- Lactobacillus GG -- probiotic -- type 1 diabetes (T1D) -- proinflammatory cytokines; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2019.1633877
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: This study was planned to evaluate whether a 3-month treatment with Lactobacillus rhamnosus GG (LGG) can modify immune system functions in children and adolescents with type 1 diabetes (T1D), leading to an increased immune response to an injectable quadrivalent inactivated influenza vaccine (QIV). A total of 87 pediatric patients with T1D were screened, although 34 patients in the Probiotic group and 30 in the Control group accepted to be vaccinated with QIV and completed the study. Vaccine immunogenicity and safety and the inflammatory cytokine response were studied. Results showed that QIV was immunogenic and safe in T1D pediatric patients and pre-administration of LGG for three months did not substantially modify the QIV humoral immunity. The combination of QIV and LGG reduced inflammatory responses (i.e., IFN-γ, IL17A, IL-17F, IL-6, and TNF-α) from activated PBMCs of pediatric patients with T1D, without dampening the production of seroprotective antibodies. In conclusion, QIV is associated with an adequate immunogenicity in children and adolescents with T1D in presence of a good safety profile. Although a systematic administration of LGG did not result in an improvement of humoral responses to an influenza vaccine, the probiotic did induce important anti-inflammatory effects.